Exagen (NASDAQ: XGN) owner buys 14,000 shares in new insider filing

What happened

Exagen Inc. (NASDAQ: XGN) filed a Form 4 showing Jorey Chernett, a director and 10% owner, bought 14,000 common shares on 2026-10-19. The filing lists the trade as a purchase, and the form was signed on 2026-10-20.

The shares changed hands at a weighted average price of $7.46, with purchases ranging from $7.44 to $7.48, for about $104,440. The filing says the price is rounded to the nearest cent and reflects multiple transactions.

After the purchase, Chernett reported 2,618,540 shares beneficially owned directly. The filing is narrow, but it gives investors an exact ownership update from a large holder in one report.

Key numbers

Metric	Latest	Change	Source
Shares purchased	14,000 shares		SEC Form 4
Weighted average price	$7.46		SEC Form 4
Purchase price range	$7.44 to $7.48		SEC Form 4
Total purchase value	about $104,440		SEC Form 4
Shares held after trade	2,618,540 shares		SEC Form 4

Read more: Exagen (XGN) stock analysis and investment case

Why it matters

OptimistFi's case is that AVISE must keep gaining rheumatology adoption while preserving reimbursement and gross margin long enough for Exagen to cross into self-funded profitability. This filing is mixed for that view because it adds a fresh buy from a 10% owner, but it does not address those operating drivers.

The 14,000 shares were about 0.5% of Chernett's 2,604,540-share pre-trade holding, so the buy changes the position only a little. A single insider purchase does not prove the business is improving, and it stays limited to ownership data.

The calculation turns the filing into a size check, not a verdict. The purchase is a clear signal from a large holder, but it is still only one trade. That is enough to matter to investors, but not enough to change the operating thesis on its own.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Exagen's next quarterly report is the next dated test for this case. If it shows better AVISE adoption, steadier reimbursement or margin progress, that would strengthen the case, while weaker results would weaken it.

Until then, the filing leaves investors with a fresh ownership data point and no change to the operating thesis. That report is the best follow-up because it can show whether the ownership move lines up with business progress in the next update.

More from OptimistFi

• XGN stock: the Exagen thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps